Sirtris Pharmaceuticals, a biopharmaceutical company focused on discovering and
developing small molecule drugs to treat diseases of aging, announced
preclinical data showing that SRT501, when orally administered, slows retinal
ganglion cell loss during optic neuritis, a neurodegenerative eye disorder, and
suppresses neurological dysfunction in a preclinical model of Multiple
Sclerosis.
